3IPSC : Demystifying Century Therapeutics: Insights From 4 Analyst Reviews
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.0, a ...
Century Therapeutics price target lowered to $5 from $12 at Guggenheim
Guggenheim analyst Kelsey Goodwin lowered the firm’s price target on Century Therapeutics (IPSC) to $5 from $12 and keeps a Buy rating on the ...
Century Therapeutics (IPSC) Receives a Buy from Piper Sandler
In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Century Therapeutics (IPSC – Research Report), with a ...